R&D Closed & Collaborative H2 2025: Mergers, acquisitions, partn... The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.
News Gilead strikes deal to expand HIV drug access in 120 countri... Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free
Market Access SteinCares and Sandoz: Bringing high-quality healthcare prod... Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.